NRG 200 Pharmacology for Human Caring Nursing - Final
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions - 169 Questions with Answers
NRG 200 Pharmacology for Human Caring Nursing Final Exam 2026-169 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NRG 200 Pharmacology for Human Caring
Nursing contains 200 verified questions and answers, meticulously curated to align with the 2026/2027
academic year. It covers essential pharmacological principles, drug classifications, nursing
implications, and patient education, ensuring a thorough review for the final exam. Each question is
paired with a correct answer and rationale, facilitating active recall and deeper understanding. This
resource is an indispensable tool for nursing students aiming to excel in their pharmacology final.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Nursing process in medication administration
Patient safety and adverse effects monitoring
Client education and health promotion
Legal and ethical considerations in pharmacology
Updates for 2026:
- Updated to reflect the latest 2026/2027 NCLEX-RN test plan and pharmacology guidelines
- Revised to include current evidence-based practice in medication administration
- Enhanced rationales with expanded explanations for correct and incorrect options
- Incorporated new questions on recently approved medications and black box warnings
- Aligned with the latest safety standards from the Institute for Safe Medication Practices (ISMP)
Abstract:
This exam preparation document is a scholarly compilation designed to support nursing students in mastering
pharmacology within the context of human caring. It integrates core pharmacological concepts with the nursing
process, emphasizing safe and compassionate medication administration. The 200 questions are strategically
distributed across major content areas, including drug classifications, pharmacokinetics, pharmacodynamics, and
therapeutic applications. Each question is accompanied by a verified correct answer and a detailed rationale that
explains the underlying scientific principles and clinical reasoning. The document also highlights critical nursing
interventions, patient education points, and potential adverse effects, fostering a holistic approach to
pharmacological care. By engaging with this material, students can enhance their critical thinking skills and
readiness for the final exam, ultimately promoting patient safety and positive health outcomes.
Keywords:
NRG 200, Pharmacology, Nursing, Final Exam, Verified Questions, NCLEX, Drug Classifications, Patient Safety
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer clearly indicated. A
comprehensive rationale is provided for each answer, explaining why it is correct and why the other options are
incorrect, thereby reinforcing key pharmacological concepts and clinical reasoning.
Compliance Checklist:
Aligns with the 2026/2027 NCLEX-RN test plan
Page 1
, Meets the latest safety standards from the Institute for Safe Medication Practices (ISMP)
Incorporates current evidence-based practice guidelines
Includes rationales that support critical thinking and clinical judgment
Covers all major pharmacological content areas required for nursing licensure
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Drug-receptor interactions
Autonomic Nervous System 31-60 Cholinergic agonists, Anticholinergics, 15%
Drugs Adrenergic agonists, Adrenergic blockers
Cardiovascular and Renal Drugs 61-90 Antihypertensives, Diuretics, Cardiac 15%
glycosides, Antiarrhythmics, Anticoagulants
Central Nervous System Drugs 91-120 Sedatives-hypnotics, Antidepressants, 15%
Antipsychotics, Antiepileptics, Opioid
analgesics
Endocrine Drugs 121-150 Insulin, Oral hypoglycemics, Thyroid 15%
hormones, Corticosteroids, Sex hormones
Antimicrobial and 151-180 Antibiotics, Antivirals, Antifungals, 15%
Anti-inflammatory Drugs NSAIDs, Disease-modifying antirheumatic
drugs
Nursing Implications and Patient 181-200 Medication administration, Monitoring, 10%
Education Adverse effects, Client teaching,
Legal-ethical considerations
Page 2
,Q1. A patient with chronic kidney disease (eGFR 25 mL/min) requires treatment for
atrial fibrillation. Which anticoagulant strategy is most appropriate, considering the
need to avoid dose adjustment and monitoring?
A. Warfarin with frequent INR monitoring
B. Apixaban at a reduced dose
C. Rivaroxaban at the standard dose
D. Enoxaparin with anti-Xa monitoring
Correct Answer: B. Apixaban at a reduced dose
Rationale: Apixaban has the most favorable pharmacokinetic profile in renal impairment,
with only a 50% dose reduction required for eGFR 15-29 mL/min, and no routine
monitoring is needed. Warfarin requires INR monitoring, rivaroxaban is not recommended
in severe renal impairment, and enoxaparin requires anti-Xa monitoring.
Why Wrong:
A - Warfarin requires frequent INR monitoring and has multiple drug and food
interactions.
C - Rivaroxaban is not recommended in patients with eGFR <30 mL/min due to
increased bleeding risk.
D - Enoxaparin requires anti-Xa monitoring and is not an oral option for long-term
anticoagulation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q2. A patient on long-term phenytoin therapy develops gingival hyperplasia. The
prescriber considers switching to another antiepileptic. Which alternative has the
LEAST potential for this adverse effect and similar enzyme-inducing properties?
A. Carbamazepine
B. Valproic acid
C. Levetiracetam
D. Phenobarbital
Correct Answer: C. Levetiracetam
Rationale: Levetiracetam is not associated with gingival hyperplasia and does not induce
hepatic enzymes, unlike phenytoin, carbamazepine, and phenobarbital. Valproic acid is an
enzyme inhibitor, not inducer, but still not the best choice due to other side effects.
Why Wrong:
A - Carbamazepine is also an enzyme inducer and can cause similar adverse effects.
B - Valproic acid is not an enzyme inducer, but it has its own serious adverse effects
and is not the best alternative.
D - Phenobarbital is a potent enzyme inducer and can also cause gingival hyperplasia.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 23
Page 3
, Q3. A patient is prescribed an ACE inhibitor for heart failure. The nurse notes a
persistent dry cough. The prescriber decides to switch to an angiotensin II receptor
blocker (ARB). Which statement accurately reflects the pharmacological basis for
this change?
A. ARBs do not cause hyperkalemia, unlike ACE inhibitors.
B. ARBs directly block the AT1 receptor, avoiding bradykinin accumulation.
C. ARBs are more effective than ACE inhibitors in reducing mortality.
D. ARBs have a lower risk of angioedema because they do not affect the
renin-angiotensin system.
Correct Answer: B. ARBs directly block the AT1 receptor, avoiding bradykinin
accumulation.
Rationale: ACE inhibitors increase bradykinin levels, causing the dry cough. ARBs block
angiotensin II at the AT1 receptor without affecting bradykinin metabolism, thus avoiding
this side effect. ARBs still carry a risk of angioedema, though lower, and can cause
hyperkalemia.
Why Wrong:
A - ARBs can also cause hyperkalemia due to decreased aldosterone release.
C - ARBs and ACE inhibitors have similar mortality benefits in heart failure.
D - ARBs do affect the renin-angiotensin system by blocking AT1 receptors, and
angioedema risk is not eliminated.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 19
Q4. A patient with type 2 diabetes is prescribed metformin. The nurse reviews the
medication list and notes the patient is scheduled for a cardiac catheterization with
contrast dye. What is the appropriate nursing action regarding metformin?
A. Administer metformin as usual before the procedure.
B. Hold metformin on the day of the procedure and for 48 hours after, reassessing renal
function.
C. Switch metformin to insulin permanently.
D. Increase the metformin dose to control glucose during the procedure.
Correct Answer: B. Hold metformin on the day of the procedure and for 48 hours
after, reassessing renal function.
Rationale: Metformin carries a risk of lactic acidosis with contrast dye-induced renal
failure. It should be withheld at the time of the procedure and for 48 hours after, with renal
function reassessed before restarting. This is a standard safety recommendation.
Why Wrong:
A - Continuing metformin during contrast administration increases the risk of lactic
acidosis.
C - Insulin may be used temporarily, but a permanent switch is not required.
Page 4
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions - 169 Questions with Answers
NRG 200 Pharmacology for Human Caring Nursing Final Exam 2026-169 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NRG 200 Pharmacology for Human Caring
Nursing contains 200 verified questions and answers, meticulously curated to align with the 2026/2027
academic year. It covers essential pharmacological principles, drug classifications, nursing
implications, and patient education, ensuring a thorough review for the final exam. Each question is
paired with a correct answer and rationale, facilitating active recall and deeper understanding. This
resource is an indispensable tool for nursing students aiming to excel in their pharmacology final.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Nursing process in medication administration
Patient safety and adverse effects monitoring
Client education and health promotion
Legal and ethical considerations in pharmacology
Updates for 2026:
- Updated to reflect the latest 2026/2027 NCLEX-RN test plan and pharmacology guidelines
- Revised to include current evidence-based practice in medication administration
- Enhanced rationales with expanded explanations for correct and incorrect options
- Incorporated new questions on recently approved medications and black box warnings
- Aligned with the latest safety standards from the Institute for Safe Medication Practices (ISMP)
Abstract:
This exam preparation document is a scholarly compilation designed to support nursing students in mastering
pharmacology within the context of human caring. It integrates core pharmacological concepts with the nursing
process, emphasizing safe and compassionate medication administration. The 200 questions are strategically
distributed across major content areas, including drug classifications, pharmacokinetics, pharmacodynamics, and
therapeutic applications. Each question is accompanied by a verified correct answer and a detailed rationale that
explains the underlying scientific principles and clinical reasoning. The document also highlights critical nursing
interventions, patient education points, and potential adverse effects, fostering a holistic approach to
pharmacological care. By engaging with this material, students can enhance their critical thinking skills and
readiness for the final exam, ultimately promoting patient safety and positive health outcomes.
Keywords:
NRG 200, Pharmacology, Nursing, Final Exam, Verified Questions, NCLEX, Drug Classifications, Patient Safety
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer clearly indicated. A
comprehensive rationale is provided for each answer, explaining why it is correct and why the other options are
incorrect, thereby reinforcing key pharmacological concepts and clinical reasoning.
Compliance Checklist:
Aligns with the 2026/2027 NCLEX-RN test plan
Page 1
, Meets the latest safety standards from the Institute for Safe Medication Practices (ISMP)
Incorporates current evidence-based practice guidelines
Includes rationales that support critical thinking and clinical judgment
Covers all major pharmacological content areas required for nursing licensure
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Drug-receptor interactions
Autonomic Nervous System 31-60 Cholinergic agonists, Anticholinergics, 15%
Drugs Adrenergic agonists, Adrenergic blockers
Cardiovascular and Renal Drugs 61-90 Antihypertensives, Diuretics, Cardiac 15%
glycosides, Antiarrhythmics, Anticoagulants
Central Nervous System Drugs 91-120 Sedatives-hypnotics, Antidepressants, 15%
Antipsychotics, Antiepileptics, Opioid
analgesics
Endocrine Drugs 121-150 Insulin, Oral hypoglycemics, Thyroid 15%
hormones, Corticosteroids, Sex hormones
Antimicrobial and 151-180 Antibiotics, Antivirals, Antifungals, 15%
Anti-inflammatory Drugs NSAIDs, Disease-modifying antirheumatic
drugs
Nursing Implications and Patient 181-200 Medication administration, Monitoring, 10%
Education Adverse effects, Client teaching,
Legal-ethical considerations
Page 2
,Q1. A patient with chronic kidney disease (eGFR 25 mL/min) requires treatment for
atrial fibrillation. Which anticoagulant strategy is most appropriate, considering the
need to avoid dose adjustment and monitoring?
A. Warfarin with frequent INR monitoring
B. Apixaban at a reduced dose
C. Rivaroxaban at the standard dose
D. Enoxaparin with anti-Xa monitoring
Correct Answer: B. Apixaban at a reduced dose
Rationale: Apixaban has the most favorable pharmacokinetic profile in renal impairment,
with only a 50% dose reduction required for eGFR 15-29 mL/min, and no routine
monitoring is needed. Warfarin requires INR monitoring, rivaroxaban is not recommended
in severe renal impairment, and enoxaparin requires anti-Xa monitoring.
Why Wrong:
A - Warfarin requires frequent INR monitoring and has multiple drug and food
interactions.
C - Rivaroxaban is not recommended in patients with eGFR <30 mL/min due to
increased bleeding risk.
D - Enoxaparin requires anti-Xa monitoring and is not an oral option for long-term
anticoagulation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q2. A patient on long-term phenytoin therapy develops gingival hyperplasia. The
prescriber considers switching to another antiepileptic. Which alternative has the
LEAST potential for this adverse effect and similar enzyme-inducing properties?
A. Carbamazepine
B. Valproic acid
C. Levetiracetam
D. Phenobarbital
Correct Answer: C. Levetiracetam
Rationale: Levetiracetam is not associated with gingival hyperplasia and does not induce
hepatic enzymes, unlike phenytoin, carbamazepine, and phenobarbital. Valproic acid is an
enzyme inhibitor, not inducer, but still not the best choice due to other side effects.
Why Wrong:
A - Carbamazepine is also an enzyme inducer and can cause similar adverse effects.
B - Valproic acid is not an enzyme inducer, but it has its own serious adverse effects
and is not the best alternative.
D - Phenobarbital is a potent enzyme inducer and can also cause gingival hyperplasia.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 23
Page 3
, Q3. A patient is prescribed an ACE inhibitor for heart failure. The nurse notes a
persistent dry cough. The prescriber decides to switch to an angiotensin II receptor
blocker (ARB). Which statement accurately reflects the pharmacological basis for
this change?
A. ARBs do not cause hyperkalemia, unlike ACE inhibitors.
B. ARBs directly block the AT1 receptor, avoiding bradykinin accumulation.
C. ARBs are more effective than ACE inhibitors in reducing mortality.
D. ARBs have a lower risk of angioedema because they do not affect the
renin-angiotensin system.
Correct Answer: B. ARBs directly block the AT1 receptor, avoiding bradykinin
accumulation.
Rationale: ACE inhibitors increase bradykinin levels, causing the dry cough. ARBs block
angiotensin II at the AT1 receptor without affecting bradykinin metabolism, thus avoiding
this side effect. ARBs still carry a risk of angioedema, though lower, and can cause
hyperkalemia.
Why Wrong:
A - ARBs can also cause hyperkalemia due to decreased aldosterone release.
C - ARBs and ACE inhibitors have similar mortality benefits in heart failure.
D - ARBs do affect the renin-angiotensin system by blocking AT1 receptors, and
angioedema risk is not eliminated.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 19
Q4. A patient with type 2 diabetes is prescribed metformin. The nurse reviews the
medication list and notes the patient is scheduled for a cardiac catheterization with
contrast dye. What is the appropriate nursing action regarding metformin?
A. Administer metformin as usual before the procedure.
B. Hold metformin on the day of the procedure and for 48 hours after, reassessing renal
function.
C. Switch metformin to insulin permanently.
D. Increase the metformin dose to control glucose during the procedure.
Correct Answer: B. Hold metformin on the day of the procedure and for 48 hours
after, reassessing renal function.
Rationale: Metformin carries a risk of lactic acidosis with contrast dye-induced renal
failure. It should be withheld at the time of the procedure and for 48 hours after, with renal
function reassessed before restarting. This is a standard safety recommendation.
Why Wrong:
A - Continuing metformin during contrast administration increases the risk of lactic
acidosis.
C - Insulin may be used temporarily, but a permanent switch is not required.
Page 4
